Key facts
- This page summarizes Joshua Reed's Form 4 filing for Omega Therapeutics, Inc. (OMGAQ).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 09 Feb 2024, 16:57.
Joshua Reed - 07 Feb 2024 Form 4 Insider Report for Omega Therapeutics, Inc. (OMGAQ)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- OMGAQ
- Reported as of
- 07 Feb 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 09 Feb 2024, 16:57:55 UTC
- Prior SEC filing
- 22 Jun 2023
- Next SEC filing
- 01 Jul 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Barbara Chan as Attorney-in-Fact for Joshua Reed
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Joshua Reed filed Form 4 for Omega Therapeutics, Inc. (OMGAQ) on 09 Feb 2024.
Change
- Previous filing in this sequence was filed on 22 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
OMGA
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +110,000
- Change %
- Price
- $0.000000
- Shares after
- 110,000
- Date
- 07 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 110,000
- Exercise price
- $3.59
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option vests and becomes exercisable with respect to 25% of the underlying shares on February 7, 2025 and in twelve (12) equal quarterly installments thereafter such that the option will become fully vested and exercisable on February 7, 2028, subject to the Reporting Person's continued service to the Issuer through each such vesting date.